SecurityFRAK / Market Vectors Unconventional Oil & Gas ETF (92189F668)
Institutional Owners31
Institutional Shares2,820,508
Institutional Value$ 49,302,000 USD

Institutional Stock Ownership and Shareholders

FRAK / Market Vectors Unconventional Oil & Gas ETF Institutional Ownership

Market Vectors Unconventional Oil & Gas ETF (NYSE:FRAK) has 31 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,820,508 shares. Largest shareholders include Janney Capital Management LLC, Bank Of America Corp /de/, Wells Fargo & Company/mn, Morgan Stanley, Janney Montgomery Scott LLC, Susquehanna International Group, Llp, Jane Street Group, Llc, Royal Bank Of Canada, Private Capital Management Inc, and David R. Rahn & Associates Inc..
Market Vectors Unconventional Oil & Gas ETF (NYSE:FRAK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR ROYAL BANK OF CANADA 14,345 21,613 50.67 213 378 77.46
2018-07-23 13F-HR FARMERS & MERCHANTS INVESTMENTS INC 1,933 966 -50.03 29 17 -41.38
2018-07-24 13F-HR Janney Capital Management LLC 2,004,013 1,958,666 -2.26 29,720 34,267 15.30
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 241,759 198,328 -17.96 3,585 3,469 -3.24
2018-08-14 13F-HR MORGAN STANLEY 96,178 112,604 17.08 1,426 1,970 38.15
2018-08-10 13F-HR ENVESTNET ASSET MANAGEMENT INC 9,389 9,389 0.00 139 164 17.99
2018-08-13 13F-HR ADVANTAGE INVESTMENT MANAGEMENT, LLC 66 124 87.88 1 2 100.00
2018-08-13 13F-HR CAPTRUST FINANCIAL ADVISORS 1,073 1,073 0.00 15 19 26.67
2018-02-15 13F-HR Bb&t Investment Services, Inc. 1,530 1,530 0.00 22 24 9.09
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 265 265 0.00 4 4 0.00
2017-01-13 13F-HR MetLife Securities, Inc 1,683 31
2018-08-02 13F-HR Atlantic Trust Group, LLC 215 215 0.00 3 4 33.33
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 135 135 0.00 2 2 0.00
2018-08-14 13F-HR UBS Group AG 3,340 6,332 89.58 50 110 120.00
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 150 0 -100.00 2 0 -100.00
2018-08-07 13F-HR IFP Advisors, Inc 499 279 -44.09 7 5 -28.57
2018-08-28 13F-HR Truvestments Capital Llc 10,674 187
2018-08-08 13F-HR Price Wealth Management, Inc. 1,349 24
2018-08-13 13F-HR VAN ECK ASSOCIATES CORP 11,793 206
2017-10-26 13F-HR PRIVATE CAPITAL MANAGEMENT INC 14,750 14,750 0.00 206 219 6.31
2018-07-24 13F-HR Janney Montgomery Scott LLC 48,297 50,283 4.11 716 880 22.91
2018-08-14 13F-HR SIGNATUREFD, LLC 260 5
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 79,520 43,407 -45.41 1,179 759 -35.62
2018-08-03 13F-HR Fusion Family Wealth LLC 46 46 0.00 1 1 0.00
2018-08-10 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 600 3,589 498.17 9 63 600.00
2018-07-19 13F-HR David R. Rahn & Associates Inc. 0 13,917 0 243
2018-08-14 13F-HR Centaurus Financial, Inc. 441 8
2018-07-30 13F-HR Parallel Advisors, LLC 160 160 0.00 2 2 0.00
2018-08-14 13F-HR Parallax Volatility Advisers, L.P. 1 1 0.00 0 0
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 126,818 331,640 161.51 1,881 5,802 208.45
2018-08-15 13F-HR JANE STREET GROUP, LLC 10,029 22,796 127.30 149 399 167.79
2018-07-16 13F-HR SMITHFIELD TRUST CO 2,200 2,200 0.00 33 38 15.15
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 52,551 0 -100.00 779 0 -100.00

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 92189F668